Recently it was demonstated that activation of receptor tyrosine kinases HGF/MET mediated resistance to MEKi in MPNST, and points towards a useful combination of MEK and MET inhibition NF1 patients with MPNST [5]. Here, MAP2K7 is linked to malignant peripheral nerve sheath tumor.